Dr Sarah Best - ACRF Cancer Biology & Stem Cells division

Dr Sarah Best - ACRF Cancer Biology & Stem Cells division

Start Time: 
Wed, 03/06/2020 - 1:00pm
End Time: 
Wed, 03/06/2020 - 2:00pm

KEAP calm and carry on: Investigating lung adenocarcinoma through the lens of Keap1/Nrf2 pathway activation

Online seminar: access Slido and enter code #WEHIWEDNESDAY
Including Q&A session

​The KEAP1/NRF2 pathway is a key regulator of the oxidative stress response, which is hijacked in cancer cells. KEAP1-mutant lung cancers are an aggressive chemo- and radio-therapy resistant subtype for which no personalised treatment options are available in the clinic, resulting in poor outcomes for patients. Recently, we have set up a research program to undertake a multi-parametric approach to understand KEAP1-mutant lung cancer, which has elucidated key aspects of lung adenocarcinoma pathology and novel metabolic treatment modalities. Keap1-deficient lung adenocarcinomas arise from a bronchiolar cell-of-origin, resulting in a unique immune microenvironment lacking pro-tumorigenic macrophages, which are observed in tumours originating from alveolar cells. Furthermore, Keap1 loss results in altered Pentose Phosphate Pathway metabolism that is a key vulnerability in KEAP1-mutant tumours as a drug target and metabolic biomarker.

Sarah Best is a Senior Postdoctoral Fellow in the Sutherland Laboratory. After completing her PhD in the Visvader/Lindeman Laboratory at WEHI, Sarah went to the Brigham and Women’s Hospital in Boston and returned to WEHI in 2016. Her interest lies in the genetics of solid tumours, with a focus on the design of personalised therapeutics for patient